119 related articles for article (PubMed ID: 1522691)
21. Molecular forms of plasminogen activator inhibitor-1 (PAI-1) and tissue-type plasminogen activator (t-PA) in human plasma.
Alessi MC; Juhan-Vague I; Declerck PJ; Collen D
Thromb Res; 1991 May; 62(4):275-85. PubMed ID: 1907771
[TBL] [Abstract][Full Text] [Related]
22. Plasminogen activators and plasminogen activator inhibitors in liver deficiencies caused by chronic alcoholism or infectious hepatitis.
Tran-Thang C; Fasel-Felley J; Pralong G; Hofstetter JR; Bachmann F; Kruithof EK
Thromb Haemost; 1989 Sep; 62(2):651-3. PubMed ID: 2510345
[TBL] [Abstract][Full Text] [Related]
23. Interrelationship between coagulant activity and tissue-type plasminogen activator (t-PA) system in acute ischaemic heart disease. Possible role of the endothelium.
Munkvad S; Jespersen J; Gram J; Kluft C
J Intern Med; 1990 Oct; 228(4):361-6. PubMed ID: 1702458
[TBL] [Abstract][Full Text] [Related]
24. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
Munkvad S
Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
[TBL] [Abstract][Full Text] [Related]
25. Effect of PAI-1 levels on the molar concentrations of active tissue plasminogen activator (t-PA) and t-PA/PAI-1 complex in plasma.
Chandler WL; Trimble SL; Loo SC; Mornin D
Blood; 1990 Sep; 76(5):930-7. PubMed ID: 2118399
[TBL] [Abstract][Full Text] [Related]
26. Plasminogen activator inhibitor activity as a possible indicator of disease activity in rest angina with angiographically insignificant coronary artery stenosis.
Sakata K; Kurata C; Kobayashi A; Rydzewski A; Yamazaki N
Thromb Res; 1991 Sep; 63(5):491-502. PubMed ID: 1755002
[TBL] [Abstract][Full Text] [Related]
27. [Evaluation of a new enzyme immunoassay method for determination of t-PA-PAI-1 complex].
Kuroso K; Shinozawa K; Sato T; Fukutake K; Fujimaki M
Rinsho Byori; 1991 Jun; 39(6):610-4. PubMed ID: 1908914
[TBL] [Abstract][Full Text] [Related]
28. [Tissue plasminogen activator (T-PA) and tissue plasminogen activator inhibitor (PAI-1) in patients after head injury].
Beuth W; Kotschy M; Kasprzak HA; Rość D; Osiński P; Sniegocki M
Neurol Neurochir Pol; 1996; 30(3):427-34. PubMed ID: 8965977
[TBL] [Abstract][Full Text] [Related]
29. Effect of niceritrol on fibrinolysis and lipoprotein (a) levels in patients with coronary artery disease.
Suefuji H; Ogawa H; Yasue H; Imoto N; Sakamoto T; Miyao Y; Kaikita K; Soejima H; Nishiyama K
Coron Artery Dis; 1996 Feb; 7(2):167-72. PubMed ID: 8813450
[TBL] [Abstract][Full Text] [Related]
30. Activation and inhibition of fibrinolysis in septic patients in an internal intensive care unit.
Voss R; Matthias FR; Borkowski G; Reitz D
Br J Haematol; 1990 May; 75(1):99-105. PubMed ID: 1695855
[TBL] [Abstract][Full Text] [Related]
31. Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications.
Lucore CL; Sobel BE
Circulation; 1988 Mar; 77(3):660-9. PubMed ID: 2449299
[TBL] [Abstract][Full Text] [Related]
32. [Problems in measuring parameters of the fibrinolytic system: circadian rhythm of tissue-type plasminogen activator and plasminogen activator inhibitor].
Köhler M; Miyashita C
Klin Wochenschr; 1988; 66 Suppl 12():62-7. PubMed ID: 3126347
[TBL] [Abstract][Full Text] [Related]
33. Fibrinogen, coagulation factor VII, tissue plasminogen activator, plasminogen activator inhibitor-1, and lipid as cardiovascular risk factors in chronic hemodialysis and continuous ambulatory peritoneal dialysis patients.
Tomura S; Nakamura Y; Doi M; Ando R; Ida T; Chida Y; Ootsuka S; Shinoda T; Yanagi H; Tsuchiya S; Marumo F
Am J Kidney Dis; 1996 Jun; 27(6):848-54. PubMed ID: 8651250
[TBL] [Abstract][Full Text] [Related]
34. Fibrinolytic and inflammatory processes in pleural effusions.
Philip-Joët F; Alessi MC; Philip-Joët C; Aillaud M; Barriere JR; Arnaud A; Juhan-Vague I
Eur Respir J; 1995 Aug; 8(8):1352-6. PubMed ID: 7489803
[TBL] [Abstract][Full Text] [Related]
35. Changes in plasma levels of tissue-plasminogen activator/inhibitor complex and active plasminogen activator inhibitor in patients with disseminated intravascular coagulation.
Asakura H; Jokaji H; Saito M; Uotani C; Kumabashiri I; Morishita E; Yamazaki M; Matsuda T
Am J Hematol; 1991 Mar; 36(3):176-83. PubMed ID: 1899963
[TBL] [Abstract][Full Text] [Related]
36. Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1).
Angleton P; Chandler WL; Schmer G
Circulation; 1989 Jan; 79(1):101-6. PubMed ID: 2491971
[TBL] [Abstract][Full Text] [Related]
37. Baseline fibrinolytic state and the risk of future venous thrombosis. A prospective study of endogenous tissue-type plasminogen activator and plasminogen activator inhibitor.
Ridker PM; Vaughan DE; Stampfer MJ; Manson JE; Shen C; Newcomer LM; Goldhaber SZ; Hennekens CH
Circulation; 1992 May; 85(5):1822-7. PubMed ID: 1572039
[TBL] [Abstract][Full Text] [Related]
38. Correlations between t-PA and PAI-1 antigen and activity and t-PA/PAI-1 complexes in plasma of control subjects and of patients with increased t-PA or PAI-1 levels.
Alessi MC; Juhan-Vague I; Declerck PJ; Anfosso F; Gueunoun E; Collen D
Thromb Res; 1990 Dec; 60(6):509-16. PubMed ID: 2127964
[No Abstract] [Full Text] [Related]
39. Daytime fluctuations in blood of tissue-type plasminogen activator (t-PA) and its fast-acting inhibitor (PAI-1).
Kluft C; Jie AF; Rijken DC; Verheijen JH
Thromb Haemost; 1988 Apr; 59(2):329-32. PubMed ID: 3133814
[TBL] [Abstract][Full Text] [Related]
40. Effect of purified eicosapentaenoate ethyl ester on fibrinolytic capacity in patients with stable coronary artery disease and lower extremity ischaemia.
Tsuruta K; Ogawa H; Yasue H; Sakamoto T; Miyao Y; Tanae H; Kaiga K
Coron Artery Dis; 1996 Nov; 7(11):837-42. PubMed ID: 8993942
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
